Cristin-resultat-ID: 1824323
Sist endret: 18. november 2020, 09:10
NVI-rapporteringsår: 2020
Resultat
Vitenskapelig artikkel
2020

Personalized Medicine in Rheumatoid Arthritis: How Immunogenicity Impacts Use of TNF Inhibitors

Bidragsytere:
  • Caterina Bodio
  • Claudia Grossi
  • Francesca Pregnolato
  • Ennio Giulio Favalli
  • Martina Biggioggero
  • Antonio Marchesoni
  • mfl.

Tidsskrift

Autoimmunity Reviews
ISSN 1568-9972
e-ISSN 1873-0183
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2020
Publisert online: 2020
Trykket: 2020
Volum: 19
Hefte: 5

Beskrivelse Beskrivelse

Tittel

Personalized Medicine in Rheumatoid Arthritis: How Immunogenicity Impacts Use of TNF Inhibitors

Sammendrag

Up to 40% of patients treated with tumor necrosis factor alpha inhibitors (TNFi) do not respond to therapy. Testing drug bioavailability and/or anti-drug antibody (ADAb) levels may justify dosage adjustment or switch to different drugs, enabling a personalized medicine approach. We report a multicenter cross-sectional study on different methods [ELISA and a cell based functional assay (reporter gene assay - RGA)] for drug/ADAb detection, and on the relationship between drug bioavailability and ADAb. 163 patients with rheumatoid arthritis (RA) treated with infliximab (IFX; n = 67), adalimumab (ADL; n = 49) or etanercept (ETA; n = 47) were tested for drug and ADAb levels. Furthermore, we report prospective data from additional 70 patients (59 RA and 11 juvenile idiopathic arthritis - JIA) tested for drug and ADAb levels at baseline (T0) and after 3 (T3) and 6 months (T6) of treatment with ADL or ETA only. IFX-treated patients were not included because of the increasing use of IFX biosimilars. Stringent inclusion criteria were used in order to avoid unwanted variables in both studies; none of the patients used TNFi before the study, and TNFi was used only in combination with methotrexate. Clinical response was defined according to EULAR response criteria. The two assays performed comparably in the comparison study. Accordingly, ELISA was selected for the prospective study because of its feasibility in the clinical setting. The cross-sectional study found ADAb in IFX and ADL treated groups only, that were associated with a decrease in pharmacological drug availability in the blood. Comparable results were found for the ADL-treated group in the prospective study which also showed a relationship between drug/ADAb levels and the loss of clinical response. Altogether our findings support drug and anti-drug Ab monitoring in the real-world clinical setting thus enabling individualized treatment and reducing disability in chronic inflammatory arthritis.

Bidragsytere

Caterina Bodio

  • Tilknyttet:
    Forfatter

Claudia Grossi

  • Tilknyttet:
    Forfatter

Francesca Pregnolato

  • Tilknyttet:
    Forfatter

Ennio Giulio Favalli

  • Tilknyttet:
    Forfatter

Martina Biggioggero

  • Tilknyttet:
    Forfatter
1 - 5 av 19 | Neste | Siste »